AIM ImmunoTech Inc.
AIM ImmunoTech Inc. (AIM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AIM · as of Jun 30, 2025
Ownership Breakdown
1
Institutional Holders
▼ 31 vs Q1
$200
Total Inst. Value
▼ $589,831 vs Q1
3.40M
Shares Outstanding
freeFloat 81.62%
1,001
13F Shares Held
▼ 4.83M vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AIM largest shareholders · institutional ownership
Q2 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ADVISOR GROUP HOLDINGS, INC. biological products, (no diagnostic substances) | 1.0K | 4.93% | 4.93% | $200,000 | Aug 13, 2025 | — held |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2025 | EXIT |
HARBOUR INVESTMENTS, INC. biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Jul 28, 2025 | EXIT |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 13, 2025 | EXIT |
STATE STREET CORP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2025 | EXIT |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 11, 2025 | EXIT |
WELLS FARGO & COMPANY/MN biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2025 | EXIT |
MORGAN STANLEY biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 15, 2025 | EXIT |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 13, 2025 | EXIT |
HUNTINGTON NATIONAL BANK biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 5, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2025 vs prior quarter
Q2 2025
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares31
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-31
0 new / 31 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AIM insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Equels Thomas K CEO & President | Mar 12, 2026 | C-Conversion | 25,000 | — | — | 63.9K | Form 4 ↗ |
Equels Thomas K CEO & President | Mar 12, 2026 | C-Conversion | 25 | — | — | 0 | Form 4 ↗ |
CHEMEROW DAVID I. director | Mar 12, 2026 | C-Conversion | 25,000 | — | — | 28.4K | Form 4 ↗ |
CHEMEROW DAVID I. director | Mar 12, 2026 | C-Conversion | 25 | — | — | 0 | Form 4 ↗ |
Equels Thomas K CEO & President | Mar 6, 2026 | J-Other | 50,000 | $1.00 | $50.0K | 50.0K | Form 4 ↗ |
Equels Thomas K CEO & President | Mar 6, 2026 | J-Other | 25 | $1000.00 | $25.0K | 25 | Form 4 ↗ |
CHEMEROW DAVID I. director | Mar 6, 2026 | J-Other | 50,000 | $1.00 | $50.0K | 50.0K | Form 4 ↗ |
CHEMEROW DAVID I. director | Mar 6, 2026 | J-Other | 25 | $1000.00 | $25.0K | 25 | Form 4 ↗ |
CHEMEROW DAVID I. director | Feb 5, 2026 | Award | 2,800 | $1.23 | $3.4K | 3.4K | Form 4 ↗ |
Equels Thomas K CEO & President | Jun 13, 2025 | Purchase | 107 | $7.70 | $823.579 | 38.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
AIM ImmunoTech Inc. (AIM) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 18.38%, while retail and public investors account for the remaining 81.59%.
The largest institutional shareholder of AIM ImmunoTech Inc. is ADVISOR GROUP HOLDINGS, INC., holding approximately 1,001 shares — equal to 4.93% of outstanding shares — as of June 30, 2025.
A total of 1 institutional investors currently hold AIM stock, with a combined institutional value of approximately $200 as of the most recent 13F filing period.
Frequently asked questions
AIM ownershipAIM ImmunoTech Inc. (AIM) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is ADVISOR GROUP HOLDINGS, INC. with a 4.93% stake. Company insiders hold 18.38%. Data sourced from SEC Form 13F as of June 30, 2025.